利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.017 秒)

    HIGH PENETRATION COMPOSITION AND USES THEREOF
    1.
    发明申请
    HIGH PENETRATION COMPOSITION AND USES THEREOF 审中-公开

    公开(公告)号：US20170151337A1

    公开(公告)日：2017-06-01

    申请号：US15379866

    申请日：2016-12-15

    申请人： Techfields Pharma Co., Ltd.

    发明人： Chongxi YU ,  Lina XU

    IPC分类号： A01N37/36 ,  A61K9/00 ,  A61K31/167 ,  A61K31/612 ,  C07C233/25 ,  A61K9/70

    CPC分类号： A61K9/0014 ,  A61K9/7023 ,  A61K31/167 ,  A61K31/22 ,  A61K31/612 ,  A61K47/54 ,  A61K47/542 ,  C07C231/12 ,  C07C233/25

    摘要： The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.

    Modified release formulations and methods of treating inflammatory bowel disease
    2.
    发明授权
    Modified release formulations and methods of treating inflammatory bowel disease 有权
    改善释放制剂和治疗炎性肠病的方法

    公开(公告)号：US07825106B2

    公开(公告)日：2010-11-02

    申请号：US11371958

    申请日：2006-03-10

    申请人： John Devane ,  Jackie Butler

    发明人： John Devane ,  Jackie Butler

    IPC分类号： A61K31/60 ,  A61K31/603 ,  A61K31/606 ,  A61K31/609 ,  A61K31/612 ,  A61K31/616 ,  A61K31/618 ,  A61K31/625

    CPC分类号： A61K9/2054 ,  A61K9/2031 ,  A61K31/60 ,  A61K31/606 ,  A61K31/655 ,  C07C245/08 ,  C07C251/84

    摘要： Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

    摘要翻译： 公开了治疗炎症性肠病的方法和制剂。 方法和制剂包括但不限于用于将有效浓度的4-氨基水杨酸和/或5-氨基水杨酸及其药学上可接受的盐和前药递送到受影响的肠的区域的方法和制剂，即 ，远端肠道 方法和制剂包含修饰释放元件，提供药物递送到受影响的或期望的区域。 可用本发明治疗的疾病和病症包括克罗恩病和溃疡性结肠炎。

    HIGH PENETRATION COMPOSITION AND USES THEREOF
    8.
    发明申请
    HIGH PENETRATION COMPOSITION AND USES THEREOF 有权

    公开(公告)号：US20220096370A1

    公开(公告)日：2022-03-31

    申请号：US17493321

    申请日：2021-10-04

    申请人： TECHFIELDS PHARMA CO., LTD

    发明人： Chongxi Yu ,  Lina Xu

    IPC分类号： A61K9/00 ,  C07C233/25 ,  A61K31/22 ,  C07C231/12 ,  A61K47/54 ,  A61K9/70 ,  A61K31/167 ,  A61K31/612

    摘要： The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.